ERBB2 and breast carcinoma: This cohort study examines racial and ethnic disparities in the receipt of ERBB2 (formerly HER2 or HER2/neu)–targeted therapies and changes in receipt over time among Medicare beneficiaries with ERBB2-positive breast cancer.